RECRUITING

Impact of ICCAN on Cancer Treatment Completion and Quality of Life

Conditions

Cancer Patients Quality of life cancer 12-223

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this 1 year study is to see if the ICCAN program is working, and to compare the ICCAN program to the standard hospital services provided in New York City hospitals, like meeting with a Social Worker or a Patient Navigator (a person who provides personal hospital guidance).

Official Title

A Randomized Controlled Trial of the Impact of ICCAN on Cancer Treatment Completion and Quality of Life

Quick Facts

Study Start:2012-11

Study Completion:2025-11

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT01742143

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:21 Years to 80 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* fluent in English, Spanish, or Mandarin * between the ages of 21-80 years old * cancer patients currently receiving chemotherapy (started within the past month) and/or radiation therapy (started within the past week), or * scheduled to begin chemotherapy and/or radiation therapy within the next 2 months (excluding surgery only patients) * planning on remaining in the area for at least 1 year * Has an MD or DO degree * Is the treating physician providing care to a patient enrolled to the study * Is 18 - 85 years of age * Has unresectable locally advanced, locally recurrent unresectable, metastatic, or high risk/early stage TNBC or stage I-IV lung cancer * Eligible for FDA approved immunotherapy in the NYC metropolitan area (per self-report or per MSK patient EMR records). * Is treated in the NY metropolitan area * Self-identifies as Black or Hispanic, and/or is low-SES (low SES will be defined as household income \< 200% of federal poverty level) * Has English or Spanish proficiency * Agrees to be audio-recorded * Is 18 - 85 years of age * Has stage II-III TNBC * Treated at MSK Manhattan or OneMSK regional sites * Self identifies as Black or Hispanic, and/or is low SES (low SES will be defined as household income \< 200% of federal poverty level) * Has English or Spanish proficiency * Agrees to be audio-recorded * Staff member who serves as an Access Facilitator * Agrees to be audio-recorded	* Presence of untreated psychiatric disturbance (i.e. acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) verified by medical record sufficient to preclude completion of the assessment measures, interview or informed consent * Presence of untreated psychiatric disturbance (e.g., acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) sufficient to preclude completion of the assessment measures, interview or informed consent * Participants or family members who are participating in MSK IHCD studies related to social determinants of health * Presence of untreated psychiatric disturbance (e.g, acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) sufficient to preclude completion of the assessment measures, interview or informed consent * Participants or family members who are participating in MSK IHCD studies related to social determinants of health

Inclusion Criteria

Exclusion Criteria

* fluent in English, Spanish, or Mandarin
* between the ages of 21-80 years old
* cancer patients currently receiving chemotherapy (started within the past month) and/or radiation therapy (started within the past week), or
* scheduled to begin chemotherapy and/or radiation therapy within the next 2 months (excluding surgery only patients)
* planning on remaining in the area for at least 1 year
* Has an MD or DO degree
* Is the treating physician providing care to a patient enrolled to the study
* Is 18 - 85 years of age
* Has unresectable locally advanced, locally recurrent unresectable, metastatic, or high risk/early stage TNBC or stage I-IV lung cancer
* Eligible for FDA approved immunotherapy in the NYC metropolitan area (per self-report or per MSK patient EMR records).
* Is treated in the NY metropolitan area
* Self-identifies as Black or Hispanic, and/or is low-SES (low SES will be defined as household income \< 200% of federal poverty level)
* Has English or Spanish proficiency
* Agrees to be audio-recorded
* Is 18 - 85 years of age
* Has stage II-III TNBC
* Treated at MSK Manhattan or OneMSK regional sites
* Self identifies as Black or Hispanic, and/or is low SES (low SES will be defined as household income \< 200% of federal poverty level)
* Has English or Spanish proficiency
* Agrees to be audio-recorded
* Staff member who serves as an Access Facilitator
* Agrees to be audio-recorded

* Presence of untreated psychiatric disturbance (i.e. acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) verified by medical record sufficient to preclude completion of the assessment measures, interview or informed consent
* Presence of untreated psychiatric disturbance (e.g., acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) sufficient to preclude completion of the assessment measures, interview or informed consent
* Participants or family members who are participating in MSK IHCD studies related to social determinants of health
* Presence of untreated psychiatric disturbance (e.g, acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) sufficient to preclude completion of the assessment measures, interview or informed consent
* Participants or family members who are participating in MSK IHCD studies related to social determinants of health

Contacts and Locations

Study Contact

Francesca Gany, MD, MS

CONTACT

646-888-8054

Jennifer Leng, MD, MPH

CONTACT

646-888-4243

Principal Investigator

Francesca Gany, MD, MS

PRINCIPAL_INVESTIGATOR

Memorial Sloan Kettering Cancer Center

Study Locations (Sites)

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Basking Ridge, New Jersey, 07920

United States

Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

Middletown, New Jersey, 07748

United States

Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Montvale, New Jersey, 07645

United States

Lincoln Hospital and Mental Health Center

Bronx, New York

United States

Lutheran Medical Center

Brooklyn, New York, 11220

United States

Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities)

Commack, New York, 11725

United States

Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Harrison, New York, 10604

United States

City College of New York (Data Collection AND Data Analysis)

New York, New York, 10031

United States

Memorial Sloan Kettering at Ralph Lauren Center (Limited Protocol Activities)

New York, New York, 10035

United States

Memorial Sloan Kettering Cancer Center

New York, New York, 10065

United States

Memorial Sloan Kettering Nassau (Limited Protocol Activities)

Rockville Centre, New York, 11553

United States

Collaborators and Investigators

Sponsor: Memorial Sloan Kettering Cancer Center

Francesca Gany, MD, MS, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2012-11

Study Completion Date2025-11

Study Record Updates

Study Start Date2012-11

Study Completion Date2025-11

Terms related to this study

Keywords Provided by Researchers

Quality of life
cancer
12-223

Additional Relevant MeSH Terms

Cancer Patients